Figure 2. Progression-free survival and overall survival among all patients with KRAS exon 2 wild-type.

Kaplan-Meier curves for (A) progression-free survival from the start of second-line treatment, (B) overall survival from start of second-line treatment, and (C) overall survival from start of first-line treatment. The curves compare continued cetuximab plus changed chemotherapy and changed chemotherapy only as second-line treatment in all patients. Cet.: Cetuximab; Chemo.: chemotherapy. P values were determined using the log-rank test.